Penggunaan Pegfilgrastim Pada Mobilisasi Hematopoietic Stem Cells dan Progenitor Cells: Literatur Review
Abstract
Abstract
Introduction: Pegylated Filgrastim (Pegfilgrastim) is often used in supportive therapy to prevent fever due to neutropenia after chemotherapy in patients with malignancy. In addition, pegfilgrastim, which is a Granulocyte colony-stimulating factor (G-CSF), is also used to induce the production of hematopoietic stem cells/progenitor cells (HSPCs) for stem cell transplantation for various therapeutic purposes. This literature study aims to explain the pharmacokinetics and pharmacodynamics of pegfilgrastim, as well as its clinical applications, as preparation material for further experimental research.
Research Methods: This study is a literature study, the literature search was carried out using Google Scholar with the keyword pegfilgrastim, and the inclusion criteria were literature in national and international journals with a timeframe from 2011 to 2021.
Results: From the search results obtained 5000 kinds of literature, after selecting 19 kinds of literature that fall into the inclusion criteria.
Conclusion: Pegfilgrastim can be used as an agent to mobilize hematopoietic stem cells/progenitor cells.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Daftar Pustaka
Hoggatt J, Pelus LM. Mobilization of hematopoietic stem cells from the bone marrow niche to the blood compartment. Published online 2011.
Greenbaum AM, Link DC. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia. Published online 2011:211-217. doi:10.1038/leu.2010.248
Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim ( a long-acting G-CSF ) for prevention of chemotherapy-induced febrile neutropenia : consensus guidance recommendations. Published online 2017:3295-3304. doi:10.1007/s00520-017-3842-1
Herbert KE, Demosthenous L, Wiesner G, et al. Plerixafor plus peg fi lgrastim is a safe , effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells : a phase I clinical trial. Bone Marrow Transplant. 2014;(March):1056-1062. doi:10.1038/bmt.2014.112
Yang, BB., Morrow, P.K., Wu X et al. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol. 2015;75(6):11991206. https://doi.org/10.1007/s00280-015-2731-x
Rossi L, Tomao F, Russo G Lo, et al. Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100 : a pilot study. Published online 2013:457-462.
Finck B, Tang H, Civoli F, Hodge J, Kelly HO, Vexler V. Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects. Adv Ther. 2020;37(10):4291-4307. doi:10.1007/s12325-020-01459-y
Brekkan A, Lopez-lazaro L, Yngman G, et al. Research Article A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim. Published online 2018:1-14. doi:10.1208/s12248-018-0249-y
Kubo K, Miyazaki Y, Murayama T, Shimazaki R, Usui N, Urabe A. A randomized , double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE ( R ) chemotherapy for malignant lymphoma. 2016;(April):563-570. doi:10.1111/bjh.14088
Giralt S, Costa L, Schriber J, et al. Optimizing Autologous Stem Cell Mobilization Strategies and Recommendations. Biol Blood Marrow Transplant. 2014;20(3):295-308. doi:10.1016/j.bbmt.2013.10.013
Mohammadi S, Mohammadi AM, Nikbakht M, Norooznezhad AH. Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes : A Review of Guide- lines and Recommendations. 2017;11(1).
Costa, L.J., Kramer, C., Hogan, K.R., Butcher, C.D., Littleton, A.L., Shoptaw, K.B., Kang, Y. and Stuart R. Pegfilgrastim? versus filgrastim?based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012;52(11):2375-2381. https://doi.org/10.1111/j.1537-2995.2012.03579.x
Herbert KE, Gambell P, Link EK, et al. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant. 2013;(March 2012):351-356. doi:10.1038/bmt.2012.145
Najafi S, Ansari M, Kaveh V, Haghighat S. Comparing the efficacy and side-effects of PDLASTA ( Pegfilgrastim ) with PDGRASTIM ( Filgrastim ) in breast cancer patients : a non-inferiority randomized clinical trial. Published online 2021:1-12.
Bellon A, Wang J, Skerjanec A, et al. study in healthy volunteers to compare pharmacokinetics , pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics. 2020;(December 2019):1139-1149. doi:10.1111/bcp.14226
Waller, C.F., Tiessen, R.G., Lawrence TE et al. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol. 2018;144(4):10871095. https://doi.org/10.1007/s00432-018-2643-3
Cardonick E, Irfan F, Torres N. The Use of Neupogen ( Filgrastim ) or Neulasta ( Pegfilgrastim ) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment. 2012;2012(April):157-161.
Zhu X, Zhang W, Zhang Y, Wang Y, Hu H. Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients : A systematic review and single-arm meta-analysis. Published online 2020:1-10.
S. E. Anaya Aguirre, V. Wanzke Del Angel, H. Rivera Marquez, M. Villasis Keever, E. Lopez Aguilar FCD. Randomized double-blind controlled trial (RCT) of pegfilgrastim as prophylactic therapy in pediatric patients with solid tumors during myelosuppressive chemotherapy. J Clin Oncol. 2011;29(15):9565-9565. doi: 10.1200/jco.2011.29.15_suppl.9565
DOI: https://doi.org/10.30596/jih.v2i1.7594
Refbacks
- There are currently no refbacks.
Fakultas Kedokteran
Universitas Muhammadiyah Sumatera Utara
Jln.Gedung Arca No. 53 Medan 20217
Telp/HP/Whatsapp: +62 8112570085, +62 857-6248-0974
Website : http://jurnal.umsu.ac.id/index.php/JIH/index
Email : implementahusada@umsu.ac.id